title: Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.
abstract: Despite their multifactorial etiology, male lower urinary tract symptoms (LUTS) have been traditionally associated with benign prostatic enlargement (BPE) because of benign prostatic hyperplasia (BPH). Several pharmaceutical therapies have been used to manage LUTS, with α1-adrenergic receptor antagonists (α1-blockers) and inhibitors of 5α-reductase (5α-RIs) representing the most commonly prescribed agents currently in use for LUTS treatment. Due to their different modes of action, combined use of α1-blockers and 5α-RIs has been proven to offer more optimal control of symptoms and better associated quality of life, even though higher rates of adverse events have been shown. Following previous studies on the separate administration of dutasteride and tamsulosin, a fixed-dose combination capsule of tamsulosin 0.4 mg and dutasteride 0.5 mg has been approved and released for clinical use in men with BPH. The present review aims to discuss the rationale behind the combined use of tamsulosin and dutasteride for treating male LUTS, and to present the available data on the role of combination therapy in the management of BPH-related symptoms in terms of efficacy and safety. Special attention is given to the impact of combination treatment on the prevention of clinical progression of BPH. Cost-effectiveness of fixed-dose combination and patients' adherence to treatment are also discussed.
authors.affiliation: Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Dimitropoulos
authors.affiliation: Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Feidiou 6-8, Larissa 41221, Greece.
authors.forename: Stavros
authors.initials: S
authors.lastname: Gravas
keywords: LUTS; benign prostatic hyperplasia; dutasteride; fixed dose combination; tamsulosin
references.citation: Eur Urol. 2015 Jun;67(6):1099-109
references.pmid: 25613154
references.citation: Curr Med Res Opin. 2009 Nov;25(11):2663-9
references.pmid: 19757985
references.citation: Urol Int. 2012;88(2):177-82
references.pmid: 22179115
references.citation: Urology. 2003 Jan;61(1):37-49
references.pmid: 12559262
references.citation: Cochrane Database Syst Rev. 2002;(4):CD003851
references.pmid: 12519611
references.citation: Ther Adv Urol. 2012 Oct;4(5):267-72
references.pmid: 23024707
references.citation: BJU Int. 2013 Sep;112(5):638-46
references.pmid: 23356792
references.citation: N Engl J Med. 2010 Apr 1;362(13):1192-202
references.pmid: 20357281
references.citation: Can Urol Assoc J. 2013 May-Jun;7(5-6):E393-401
references.pmid: 23826050
references.citation: Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
references.pmid: 17049716
references.citation: BJU Int. 2006 Jan;97(1):73-9; discussion 79-80
references.pmid: 16336332
references.citation: Can Urol Assoc J. 2014 Jan-Feb;8(1-2):E1-7
references.pmid: 24454593
references.citation: J Urol. 2011 May;185(5):1793-803
references.pmid: 21420124
references.citation: BJU Int. 2015 Sep;116(3):450-9
references.pmid: 25565364
references.citation: J Urol. 2006 Apr;175(4):1422-6; discussion 1426-7
references.pmid: 16516013
references.citation: Prostate. 2009 Jun 1;69(8):895-907
references.pmid: 19267353
references.citation: Prostate Cancer Prostatic Dis. 1998 Dec;1(6):332-335
references.pmid: 12496876
references.citation: World J Urol. 2014 Oct;32(5):1133-40
references.pmid: 24804842
references.citation: Drugs. 2008;68(4):463-85
references.pmid: 18318566
references.citation: World J Urol. 2010 Feb;28(1):9-15
references.pmid: 19956956
references.citation: Patient Prefer Adherence. 2011;5:483-90
references.pmid: 22003286
references.citation: J Urol. 1995 Nov;154(5):1770-4
references.pmid: 7563343
references.citation: N Engl J Med. 1996 Aug 22;335(8):533-9
references.pmid: 8684407
references.citation: J Urol. 2009 May;181(5):2214-21; discussion 2221-2
references.pmid: 19296986
references.citation: Actas Urol Esp. 2011 Feb;35(2):65-71
references.pmid: 21269736
references.citation: BJU Int. 2005 Sep;96(4):572-7
references.pmid: 16104912
references.citation: BMC Health Serv Res. 2007 Apr 17;7:55
references.pmid: 17439645
references.citation: BJU Int. 2012 Mar;109(5):731-8
references.pmid: 21933326
references.citation: BJU Int. 2011 May;107(9):1426-31
references.pmid: 21348912
references.citation: BMC Urol. 2014 Sep 26;14:78
references.pmid: 25255740
references.citation: N Engl J Med. 2003 Jul 17;349(3):215-24
references.pmid: 12824459
references.citation: BJU Int. 2011 Mar;107(6):946-54
references.pmid: 21332630
references.citation: BJU Int. 2008 Sep;102(8):981-6
references.pmid: 18549433
references.citation: Urology. 2003 Jan;61(1):119-26
references.pmid: 12559281
references.citation: Int J Clin Pract. 2010 Jul;64(8):1042-51
references.pmid: 20487046
references.citation: Urology. 2002 Sep;60(3):434-41
references.pmid: 12350480
references.citation: N Engl J Med. 2003 Dec 18;349(25):2387-98
references.pmid: 14681504
references.citation: Drugs. 2006;66(3):287-301
references.pmid: 16526818
references.citation: Eur Urol. 2010 Jan;57(1):123-31
references.pmid: 19825505
references.citation: Eur Urol. 2008 Sep;54(3):563-9
references.pmid: 18423969
references.citation: Eur Urol. 1998 Sep;34(3):169-75
references.pmid: 9732187
references.citation: Contemp Clin Trials. 2007 Nov;28(6):770-9
references.pmid: 17761460
references.citation: Eur Urol. 2013 Jul;64(1):118-40
references.pmid: 23541338
references.citation: Int J Urol. 2012 Nov;19(11):1031-5
references.pmid: 22774774